Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis

Yoshida, Kazue; Kubo, Akiharu; Fujita, Haruyuki; Yokouchi, Mariko; Ishii, Ken; Kawasaki, Hiroshi; Nomura, Toshifumi; Shimizu, Hiroshi; Kouyama, Keisuke; Ebihara, Tamotsu; Nagao, Keisuke; Amagai, Masayuki

doi:10.1016/j.jaci.2014.08.001

Cited by 115 publications

(108 citation statements)

References 49 publications

(67 reference statements)

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…FcεRI marks inflammatory dendritic epidermal cells that characterize AD. 45,46 Given that LC numbers are similar between the 2 groups, alterations in DC skin. Data obtained from the skin of EA patients with extrinsic AD, Asian (As) patients with extrinsic AD, and patients with psoriasis (Pso) were included.…”

Section: Discussionmentioning

confidence: 99%

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

Noda

Suárez‐Fariñas

Ungar

et al. 2015

Journal of Allergy and Clinical Immunology

497

478

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

Noda

Suárez‐Fariñas

Ungar

et al. 2015

Journal of Allergy and Clinical Immunology

497

478

View full text Add to dashboard Cite

“…During the past year, a series of publications have advanced our understanding of the role of abnormalities in innate and adaptive immune responses in patients with AD. [106][107][108][109][110][111] A polarized IL-13/IL-22 immune response is emerging as of critical importance in patients with AD. 112 This is supported by the observation that dupilumab, a humanized mAb that blocks the action of IL-4 and IL-13, can improve the skin severity of AD and the molecular signature of the inflammatory skin response in the majority of patients.…”

Section: Immunologic Responses In Patients With Admentioning

confidence: 99%

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014

Sicherer

Leung

2015

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin diseases that were reported in the Journal in 2014. Studies on food allergy suggest worrisomely high rates of peanut allergy and food-induced anaphylaxis-related hospitalizations. Evidence is mounting to support the theory that environmental exposure to peanut, such as in house dust, especially with an impaired skin barrier attributed to atopic dermatitis (AD) and loss of function mutations in the filaggrin gene, is a risk factor for sensitization and allergy. Diagnostic tests are improving, with early studies suggesting the possibility of developing novel cellular tests with increased diagnostic utility. Treatment trials continue to show the promise and limitations of oral immunotherapy, and mechanistic studies are elucidating pathways that might define the degree of efficacy of this treatment. Studies have also provided insights into the prevalence and characteristics of anaphylaxis and insect venom allergy, such as suggesting that baseline platelet-activating factor acetylhydrolase activity levels are related to the severity of reactions. Advances in drug allergy include identification of HLA associations for penicillin allergy and a microRNA biomarker/mechanism for toxic epidermal necrolysis. Research identifying critical events leading to skin barrier dysfunction and the polarized immune pathways that drive AD have led to new therapeutic approaches in the prevention and management of AD.

show abstract

“…In addition to Langerhans cells, lesional skin and nonlesional AD skin harbor a distinct population of CD1a+ cells called inflammatory dendritic cells (IDEC) which bear even more high-affinity IgE receptors than Langerhans cells [78]. Recently it has been demonstrated that activated Langerhans cells extend dendrites through the tight junctions supposedly to capture antigens from the outside, while IDEC are localized in the lower part of the epidermis [79, 80]. Antigens may also be recognized by keratinocytes via Toll-like receptors (TLR), e.g., dsRNA by TLR 3 [81], S. aureus products by TLR2/TLR-6 [82], house dust mites by TLR1/6 [83], PAR 2 [84], and pattern recognition receptor NOD2 [85].…”

Section: Pathogenenic Mechanismsmentioning

confidence: 99%

Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019

Simon

Wollenberg

Renz

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting with recurrent eczematous lesions and intense pruritus. It is common and affects both children and adults, often beginning in infancy. Due to the unpredictable disease course, its visible skin lesions, itching and scratching followed by sleeplessness, other associated atopic diseases, and behavioral and psychiatric disorders, AD is an immense burden for patients and caregivers. AD is determined by a genetic predisposition characterized by an impaired skin barrier and a T-helper-2-predominant inflammation. Restoration of the skin barrier is the main approach for treating and preventing AD. In order to cope with acute flares, usually topical corticosteroids (TCS) are applied, while topical calcineurin inhibitors (TCI) are used mainly for maintenance therapy. There is a small group of patients who are refractory to TCS and TCI and require systemic immunosuppressive drugs such as ciclosporin. Novel, targeted therapies are under clinical investigation, among which an anti-IL-4/IL-13 receptor antibody has recently been approved in several countries. As we learn to understand the pathomechanisms of AD, the characteristics of the different patient subgroups, and the effectiveness of various targeted therapies, a personalized treatment ensuring the best efficacy and safety and, probably, a disease-modifying effect will result.

show abstract

Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis

Cited by 115 publications

References 49 publications

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2014

Atopic Dermatitis: Collegium Internationale Allergologicum (CIA) Update 2019

Contact Info

Product

Resources

About